SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community anticipates a potential breakout, with some drawing comparisons to past cycles and eyeing targets. Discussions revolve around its "silver to Bitcoin's gold" narrative and the impact of its MWEB privacy feature. Traders are closely watching key price levels, with some expressing frustration over recent price action.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the OG meme coin, emphasizing the return to internet culture and the power of a strong, unified community, a CULT. The focus is on building a lasting legacy within the meme coin space, moving beyond fleeting trends and KOL influence; many are anticipating a moonshot.

Concordium is the Layer-1 blockchain built for a new era of digital trust. With mandatory, privacy-preserving identity verification built into its consensus layer, utilizing zero-knowledge proof technology. Concordium also enables Protocol-level tokens that eliminate smart contract risks by being issued directly at the consensus layer, with built-in features that provide the infrastructure for compliance-ready use cases. At its core is Smart Money - programmable, identity-embedded, and compliance-ready value that powers trusted interactions across Web3. Smart Money enables frictionless exchange, automation, and verifiable trust by design. Unlike conventional blockchains, Concordium integrates trust, accountability, and privacy into its architecture from the ground up  bridging traditional systems and Web3 to build a transparent, sustainable digital future. The name Concordium comes from the Latin concordia—meaning harmony and agreement—a reflection of its mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.

Concordium

Concordium ($CCD) is trending as community members highlight its focus on privacy and compliance, particularly its partnership with bitcoin.com. Discussion centers around Concordium's potential to lead in PayFi and its unique zero-knowledge ID system, which balances user privacy with regulatory needs. Some users express confidence in its long-term potential, viewing it as infrastructure for smart money and a solution for real-world adoption.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as the community discusses its potential, particularly highlighting its surge in active users, surpassing Solana and Ethereum. Bullish sentiment is fueled by anticipation of significant growth, with some eyeing NEAR's AI sector developments and potential breakout setups. Traders are actively analyzing entry points and watching for confirmation signals amidst market volatility.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending as the community discusses its potential for growth given the protocol's strong fee generation, with some analysts noting it is undervalued. Recent news includes Uniswap's integration with Unichain and the launch of Compact v1, which aims to facilitate cross-chain swaps. Traders are also watching for a potential breakout.

Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in Laguna Hills, CA.

Hyperion DeFi Inc.

HYPD is trending as investors discuss its strategic shift towards DeFi, particularly its investment in the HYPE token and validator partnerships. Community talking points include the potential for a short squeeze, upcoming corporate updates, and whether the company's market cap accurately reflects its HYPE holdings. Some are also discussing the potential impact of Hyunsu Jung taking on additional responsibilities within the company.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

$SWEAT is trending as users discuss its potential and real-world application, with many highlighting it as an overlooked crypto. The community is focused on staking rewards and the long-term potential of the 'move-to-earn' concept, seeing it as a way to get paid for staying active. Users are optimistic about its future, but some express concerns about wallet transfers and overall utility.

ProShares Trust - ProShares Ultra Ether ETF

ProShares Ultra Ether ETF

$ETHT is trending as traders discuss its movements in relation to Ethereum, with some questioning its tracking accuracy as a 2x leveraged ETF. Community members are weighing the ETF's potential for gains amid broader crypto market discussions, while also considering entry and exit strategies based on technical analysis and market sentiment. Recent LiquidTheta alerts highlight potential opportunities with LEAPS options on $ETHT.

The $GOLD token on Solana is a memecoin asset designed to combine the historical appeal of gold with Solana's cutting edge blockchain capabilities. It will serve as a store of value on Solana. Our mission is to create a golden community of gold enthusiasts, also known as "Golders", who share a passion for both precious metals and digital assets. At its core, the $GOLD token serves as a modern store of value, echoing the stability and reliability of traditional gold.

CyberDragon Gold

CyberDragon Gold ($GOLD, $BGL, $CRYPTO) is trending as investors discuss the company's "Mine-to-Wallet" strategy, which aims to integrate gold mining with fintech innovations like the Standard Gold Coin (SGC) and the Blue Gold One App. Community members are focused on the potential for this vertical integration to unlock gold's potential as a global currency. Bullish sentiment is supported by rising gold prices and central banks' increasing gold purchases, with some analysts anticipating further upside.

NICE Ltd. engages in the provision of enterprise software solutions and services. It operates through the following segments: Customer Engagement, and Financial Crime and Compliance Solutions. The Customer Engagement segment provides suites such as compliance and risk, workforce optimization, operational efficiency, customer experience, and sales and retention. The Financial Crime and Compliance Solutions segment includes embedded-AI solutions that identify risks and help prevent money laundering and fraud, as well as help ensure financial markets compliance in real-time. The company was founded on September 28, 1986 and is headquartered in Raanana, Israel.

NICE Ltd - ADR

NICE Systems Ltd.

NICE is trending downwards, nearing its 5-year low, with the community debating whether AI will disrupt its business model or if it's currently undervalued. Some investors express frustration with the stock's performance, especially around earnings, while others see potential for a turnaround and highlight its low P/E ratio. Recent unusual options activity and analyst coverage are also generating buzz.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D Molecular Therapeutics (NASDAQ:FDMT) Raised to Equal Weight at Morgan Stanley

Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an "underweight" rating to an "equal weight" rating in a report on Friday...

<ul class="summary-bullets"><li>4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in the study.&nbsp;</li><li>The company is currently enrolling patients into late-stage trials for the drug.</li><li>Enrollment is continuing ahead of initial projections, CEO David Kirn said. &nbsp;</li></ul>4D Molecular Therapeutics (FDMT) announced on Thursday that its experimental drug 4D-150 demonstrated consistent and durable benefits in patients with wet age-related macular degeneration in an early-to-mid-stage trial.Wet age-related macular degeneration (AMD) is an advanced form of macular degeneration where abnormal blood vessels grow in the retina, leak fluid or blood, and cause a rapid decline in central vision. The proliferation and leakage of abnormal blood vessels is stimulated by vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels. According to 4D, the disease has a high incidence, with 200,000 individuals estimated to be newly diagnosed every year in the U.S. alone.<h2 class="st-heading-2">Study Findings</h2>4D-150 showed maintenance of visual acuity and control of retinal anatomy in the study, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-announces-positive-long-term-data-phase-12-prism-clinical">said</a>. The study also reduced treatment burden as patients maintained a consistent and clinically meaningful reduction in supplemental injections in 6-month intervals following dosing with 4D-150 through up to two years of follow-up, it added.4D-150 was further well tolerated with no new safety or intraocular inflammation findings. The drug is aimed at providing multi-year, and potentially lifelong, sustained delivery of anti-VEGF from the retina with a single, safe, intravitreal injection. Anti-VEGF is a treatment that blocks the action of the vascular endothelial growth factor.The company is currently enrolling patients into late-stage trials for the drug. Enrollment is continuing ahead of initial projections, according to CEO David Kirn.“With the robust PRISM dataset and our APAC region strategic partnership with Otsuka announced last week, we are well positioned for global success in our Phase 3 4FRONT clinical trials, which continue to enroll ahead of initial projections,” he added. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company soared 13% in the pre-market session at the time of writing. On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/FDMT">FDMT stock</a> remained within the ‘bullish’ territory, while message volume remained at ‘high’ levels over the past 24 hours.FDMT stock is up 89% this year and approximately 26% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dupont-announces-2-billion-share-buyback-stock-tumble-7-today/cL2t8hLREbz">DuPont Announces $2 Billion Share Buyback: Why Did The Stock Tumble 7% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease

The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time points with up to 2 years of follow-up. 

Equity

The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time points with up to 2 years of follow-up. 


Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 208.5% in 4D Molecular Therapeutics (FDMT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -11.36% and -98.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of...

Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (4D Molecular) on behalf of the companys stockholders. Since March 2024, shares of 4D Moleculars...

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. (4D Molecular Therapeutics or...

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$10.50
Prev Close	$10.92
Open	$11.02
Dividend Yield	0.00%
50-Day Moving Average	$8.91
Beta	1.31
Avg. Volume	873,657.91
PE Ratio	-2.83

52-Week High	$12.34
52-Week Low	$2.24
Market Capitalization	$490.38M
EPS (Annual)	-$2.98
Price to Book	1.17
Revenue Per Employee	$163.00
Enterprise Value/EBITDA	N/A

FDMT
4D Molecular Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FDMT News

FDMT4D Molecular Therapeutics Inc